ArticleNature reviews. Gastroenterology & hepatology2025
Author Correction: Understanding the therapeutic toolkit for inflammatory bowel disease.
Article in Nature reviews. Gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis.Inflammopharmacology · 2025Pooled it
- STRIDE-II treatment target achievement in inflammatory bowel disease: a cross-sectional study from a tertiary IBD centre in the United Arab Emirates.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Microbial 10-oxostearic acid protects mice against colitis via the nuclear receptor PPARα.Nature microbiology · 2026Article
- Large language models for clinical decision support in gastroenterology and hepatology.Nature reviews. Gastroenterology & hepatology · 2025Review
- Diallyl disulfide attenuates DSS-induced colonic fibrosis in mice by modulating gut microbiota and Nrf2 signaling.Inflammopharmacology · 2025Article
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
Corrections and comments
- Erratum for
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
39930068What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.